Gina Battaglia, PhD

Articles

Sequenced Treatment Making Inroads in HER2-Positive Early Breast Cancer

August 2nd 2017

The introduction of targeted therapies has transformed HER2-positive breast cancer from an aggressive disease with poor outcomes to a highly manageable disease with potential for long-term survival.

Sequencing Strategies Advance Care Amid Challenges in Pancreatic Cancer

July 5th 2017

Recent developments in the treatment of metastatic pancreatic cancer have modestly improved outcomes, but reducing morbidities associated with current therapies and developing novel therapeutics will be essential for achieving durable responses and long-term survival.

Hopeful Signs in Pancreatic Cancer

June 13th 2017

Although the prognosis for patients with pancreatic cancer is often grim, there have been noteworthy improvements in outcomes through the use of current chemotherapies.

HER2+ Breast Cancer Heterogeneity Calls for Combos

May 2nd 2017

Targeted therapies have improved outcomes for HER2-positive breast cancer, which is characterized by an aggressive tumor phenotype and lower overall survival. However, questions remain on how to predict which patients will benefit from neoadjuvant or extended HER2-targeted therapies and how to treat patients with triple-positive breast cancer.

Genomic Advances Pave the Way for New Therapies in AML

March 1st 2017

In an OncLive Peer Exchange® panel, experts discussed novel cytotoxic and targeted agents in the pipeline that are likely to provide new options for treating certain individuals with acute myeloid leukemia.

Fresh Strategies Aimed at Taming GVHD

September 20th 2016

Approaches to reducing and preventing graft-versus-host-disease are being explored, including the development of ruxolitinib (Jakafi) and ibrutinib (Imbruvica) under breakthrough therapy designations.

Biomarker-Driven Trials Set Pace in Lung Cancer

August 11th 2016

Biomarker-driven trials that include multiple substudies represent a new approach for investigating which patients with lung cancer are more likely to respond to different targeted therapies and are helping to set the pace throughout the oncology field.

Biomarker Combos May Hold Key to Anti-PD-1/PD-L1 Therapy Response

July 26th 2016

The wide variability in clinical outcomes among patients undergoing anti–PD-1/PD-L1 immunotherapy has increased interest in finding biomarkers that predict response.

Indication-Specific Pricing Still a Long Way Off

December 14th 2015

Cancer drugs in the United States have increased 5- to 10-fold since 2000, but several analyses indicate that this increase in cost does not match improvements in health and overall survival.

HER2-Positive Breast Cancer Treatment Options Growing

August 25th 2015

Outcomes for patients with HER2-positive metastatic breast cancer are improving as a result of blockade strategies, and more novel agents are in the pipeline.

Molecular Imaging May Help Tailor Breast Cancer Therapies

August 13th 2015

Although many drugs are under study for patients with metastatic breast cancer, there is a pressing need to establish methods of predicting response and improving drug delivery, and researchers are looking toward molecular imaging techniques to help reach those goals.

O'Shaughnessy Details Strategies to Strengthen ER Blockade in MBC

August 11th 2015

Combining estrogen receptor blockade with targeted cell-cycle inhibitors increases therapeutic options for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer, contributing to an evolving paradigm that is moving new regimens to the forefront of the treatment timeline.

Expert Says pCR Data Support Neoadjuvant Therapy in HER2-Positive Breast Cancer

October 22nd 2014

Substantial clinical trial evidence supports the use of pathologic complete response (pCR) as a measure for evaluating neoadjuvant therapies for patients with HER2-positive breast cancer, suggesting that preoperative treatment should be the standard of care

New Tactics Needed for Adjuvant Therapy to Advance in Early HER2-Positive Breast Cancer

October 8th 2014

Recent research has shown that adding targeted agents to trastuzumab-based chemotherapy regimens in the adjuvant setting may not significantly improve outcomes in patients with early-stage HER2-positive breast cancer.

O'Shaughnessy Provides Fresh Insights Into Specificity in TNBC Therapy

August 25th 2014

Although no cytotoxic agents are currently correlated with specific subtypes of triple negative breast cancer (TNBC), recent findings indicate that targeting genomic stability, antimetastatic mechanisms, and protein expression characteristics are promising approaches for future TNBC treatments.